Status: Currently Official on 16-Feb-2025
Official Date: Official as of 01-May-2020
Document Type: USP Monographs
DocId: GUID-50B7FB81-C819-431B-B19C-D607654A371B_4_en-US
DOI: https://doi.org/10.31003/USPNF_M80560_04_01
DOI Ref: 3cv7x

Tazobactam



$C_{10}H_{12}N_4O_5S$ 300.29

4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3-methyl-7-oxo-3-(1*H*-1,2,3-triazol-1-ylmethyl)-, 4,4-dioxide, [2*S*-(2α,3β,5α)]-;

(2*S*,3*S*,5*R*)-3-Methyl-7-oxo-3-(1*H*-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 4,4-dioxide CAS RN®: 89786-04-9; UNII: SE10G96M8W.

$C_{10}H_{12}N_4O_5S \cdot ½H_2O$ 309.30 CAS RN®: 428863-55-2.

DEFINITION

Tazobactam contains NLT 98.0% and NMT 102.0% of $C_{10}H_{12}N_4O_5S$, calculated on the anhydrous basis.

IDENTIFICATION

Change to read:

• **A.** ▲**Spectroscopic Identification Tests ⟨197⟩, *Infrared Spectroscopy*: 197K**▲ (CN 1-May-2020)

• **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.

ASSAY

• **Procedure**

Mobile phase: Dissolve 1.32 g of dibasic ammonium phosphate in 750 mL of water. Adjust with 5% v/v phosphoric acid to a pH of 2.5, and dilute with water to 1000 mL. Add 30 mL of acetonitrile, mix, and pass through a filter of 0.2-µm pore size.

System suitability solution: 16 µg/mL of L-phenylalanine, 50 µg/mL of USP Tazobactam RS, and 8 µg/mL of USP Tazobactam Related Compound A RS in *Mobile phase*. Maintain the *System suitability solution* at 3° until injection. Prepare fresh daily. If an autosampler is used, replace the plastic tubing connected to the injection needle with a stainless steel assembly, and maintain at 3°. If a chilled autosampler is not used, then this solution should be injected immediately after preparation.

Standard solution: 0.5 mg/mL of USP Tazobactam RS in *Mobile phase.* Cool, and maintain the *Standard solution* at 3° until injection. If an autosampler is used, replace the plastic tubing connected to the injection needle with a stainless steel assembly, and maintain at 3°. If a chilled autosampler is not used, then this solution should be injected immediately after preparation.

Sample solution: 0.5 mg/mL of Tazobactam in *Mobile phase.* Cool, and maintain the *Sample solution* at 3° until injection. If an autosampler is used, replace the plastic tubing connected to the injection needle with a stainless steel assembly, and maintain at 3°. If a chilled autosampler is not used, then this solution should be injected immediately after preparation.

Chromatographic system

(See *Chromatography ⟨621⟩, System Suitability*.)

Mode: LC

Detector: UV 210 nm

Column: 4.6-mm × 25-cm; 5-µm packing L1

Flow rate: 1.5 mL/min

Injection size: 20 µL

System suitability

Samples: *System suitability solution* and *Standard solution*

[Note—See *Table 1* for the relative retention times.]

Suitability requirements

Resolution: NLT 6.0 between tazobactam and L-phenylalanine, *System suitability solution*

Tailing factor: NMT 1.8, *Standard solution*

Relative standard deviation: NMT 2.0%, *Standard solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of tazobactam ($C_{10}H_{12}N_4O_5S$) in the portion of Tazobactam taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response from the *Sample solution*

r_S = peak response from the *Standard solution*

C_S = concentration of USP Tazobactam RS in the *Standard solution* (mg/mL)

C_U = concentration of the *Sample solution* (mg/mL)

Acceptance criteria: 98.0%–102.0% on the anhydrous basis

IMPURITIES

- **Residue on Ignition (281):** NMT 0.1%
- **Organic Impurities**

Mobile phase, System suitability solution, Chromatographic system, and **System suitability:** Proceed as directed in the *Assay*.

Blank: *Mobile phase.* Cool, and maintain the *Blank* at 3° until injection. If an autosampler is used, replace the plastic tubing connected to the injection needle with a stainless steel assembly, and maintain at 3°. If a chilled autosampler is not used, then this solution should be injected immediately after preparation.

Sample solution: Prepare as directed in the *Assay*. Cool, and maintain the *Sample solution* at 3° until injection. If an autosampler is used, replace the plastic tubing connected to the injection needle with a stainless steel assembly, and maintain at 3°. If a chilled autosampler is not used, then this solution should be injected immediately after preparation.

Analysis

Samples: *Blank* and *Sample solution*

Ignore any peaks of the *Sample solution* that correspond to any peaks of the *Blank*.

Calculate the percentage of each impurity in the portion of Tazobactam taken:

$$\text{Result} = (r_U/r_T) \times 100$$

r_U = peak response for each impurity in the *Sample solution*

r_T = sum of all the peak responses in the *Sample solution*

Acceptance criteria: See *Table 1*.

Table 1

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Tazobactam related compound A	0.29	1.0
L-Phenylalanine	0.71	—
Tazobactam	1.0	—
Any other individual impurity	—	0.1
Total impurities[a]	—	0.3

[a] Total of all impurities other than tazobactam related compound A.

SPECIFIC TESTS

• **Bacterial Endotoxins Test ⟨85⟩:** The level of bacterial endotoxins is such that the requirements of the relevant dosage form monograph(s) in which Tazobactam is used can be met.

• **Optical Rotation,** *Specific Rotation* ⟨781S⟩

Sample solution: 10 mg/mL, in dimethylformamide

Acceptance criteria: +160° to +167° (*t* = 20°)

• **Microbial Enumeration Tests ⟨61⟩** and **Tests for Specified Microorganisms ⟨62⟩:** The total aerobic microbial count does not exceed 10^3 cfu/g, and the total combined molds and yeasts count does not exceed 10^2 cfu/g.

• **pH ⟨791⟩**

Sample solution: 2.5 mg/mL

Acceptance criteria: 1.8–2.8

• **Water Determination,** *Method I* ⟨921⟩**:** NMT 0.6% for the anhydrous form; 2.2–3.8% for the hemihydrate form

ADDITIONAL REQUIREMENTS

• **Packaging and Storage:** Preserve in well-closed containers. Store at controlled room temperature.

• **Labeling:** Where it is the hemihydrate form, the label so indicates.

• **USP Reference Standards ⟨11⟩**

USP Tazobactam RS

USP Tazobactam Related Compound A RS

(2*S*,3*S*)-2-Amino-3-methyl-3-sulfino-4-(1*H*-1,2,3-triazol-1-yl)butyric acid.

$C_7H_{12}N_4O_4S$ 248.26

Auxiliary Information - Please check for your question in the FAQs before contacting USP.

Topic/Question	Contact	Expert Committee
TAZOBACTAM	Documentary Standards Support	SM12020 Small Molecules 1
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	SM12020 Small Molecules 1

Chromatographic Database Information: Chromatographic Database

Most Recently Appeared In:
Pharmacopeial Forum: Volume No. PF 34(2)

Current DocID: GUID-50B7FB81-C819-431B-B19C-D607654A371B_4_en-US

DOI: https://doi.org/10.31003/USPNF_M80560_04_01

DOI ref: 3cv7x